Tower Research Capital (TRC)’s Lipella Pharmaceuticals LIPO Stock Holding History

Tower Research Capital (TRC)’s Portfolio LIPO Stock Details LIPO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2,708	Closed	-$6.8K	–	5444
2025 Q1	$6.8K	Buy	+2,708	New	+$7.87K	﹤0.01%	4010
2024 Q4	–	Sell	-962	Closed	-$3.63K	–	5871
2024 Q3	$3.63K	Sell	962 -3	-0.3%	-$12	﹤0.01%	4805
2024 Q2	$3.47K	Buy	965 +1	+0.1%	+$5	﹤0.01%	4886
2024 Q1	$5.28K	Buy	964 +99	+11%	+$737	﹤0.01%	4563
2023 Q4	$7.06K	Buy	865 +250	+41%	+$2.33K	﹤0.01%	4667
2023 Q3	$7.38K	Buy	615 +414	+206%	+$6.7K	﹤0.01%	4475
2023 Q2	$3.44K	Sell	201 -76	-27%	-$1.19K	﹤0.01%	5076
2023 Q1	$4K	Buy	+277	New	+$5.42K	﹤0.01%	5080

Tower Research Capital (TRC)'s LIPO Position: Q2 2025 in Review

Tower Research Capital (TRC) sold out of Lipella Pharmaceuticals (LIPO) in Q2 2025, closing a stake of 2,708 shares — an estimated $6.8K sold.

Tower Research Capital (TRC) first reported a position in LIPO in Q1 2023 and held it in 8 quarters. The position peaked at $7.38K in Q3 2023. 0 funds tracked by Wall St. Rank hold LIPO as of Q2 2025.

Tower Research Capital (TRC) reported no remaining Lipella Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Tower Research Capital (TRC) sold 2,708 Lipella Pharmaceuticals shares in Q2 2025, an estimated $6.8K.
Tower Research Capital (TRC) first reported a position in Lipella Pharmaceuticals in Q1 2023 and held it in 8 quarters.
Tower Research Capital (TRC)'s Lipella Pharmaceuticals position peaked at $7.38K in Q3 2023.
0 funds tracked by Wall St. Rank held Lipella Pharmaceuticals as of Q2 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2025, filed 15 Aug 2025.